Results 21 to 30 of about 999,769 (295)

Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis

Drugs, 2023
Idiopathic pulmonary fibrosis (IPF) remains a disease with poor survival. The pathogenesis is complex and encompasses multiple molecular pathways. The first-generation antifibrotics pirfenidone and nintedanib, approved more than 10 years ago, have been ...
F. Bonella, P. Spagnolo, C. Ryerson
semanticscholar   +1 more source

Association of FcγRIIa R131H polymorphism with idiopathic pulmonary fibrosis severity and progression [PDF]

, 2010
Background A significant genetic component has been described for idiopathic pulmonary fibrosis (IPF). The R131H (rs1801274) polymorphism of the IgG receptor FcγRIIa determines receptor affinity for IgG subclasses and is associated with several chronic ...
Hart Simon P, Wallace, William A., McFarlane, Pauline, Bournazos, Stylianos, Bournazos Stylianos, Alexander, Karen M, Karen M Alexander, Jacob Grinfeld, William A Wallace, Simpson A John, Hirani, Nikhil, McFarlane Pauline, Pauline McFarlane, Grinfeld Jacob, Grinfeld, Jacob, Hirani Nikhil, Simpson, A John, John T Murchison, Nikhil Hirani, Wallace William A, Hart, Simon P, Simpson, A. John, Dransfield, Ian, Stylianos Bournazos, Murchison John T, Alexander Karen M, Murchison, John T, Wallace, William, Ian Dransfield, Dransfield Ian, A John Simpson, Simon P Hart   +31 more
core   +2 more sources

Imaging in idiopathic pulmonary fibrosis: diagnosis and mimics

Clinics, 2019
Idiopathic pulmonary fibrosis is a chronic disease of unknown etiology that usually has a progressive course and is commonly associated with a poor prognosis. The main symptoms of idiopathic pulmonary fibrosis, including progressive dyspnea and dry cough,
Bruno Hochhegger, Edson Marchiori, Matheus Zanon, Adalberto Sperb Rubin, Renata Fragomeni, Stephan Altmayer, Carlos Roberto Ribeiro Carvalho, Bruno Guedes Baldi   +7 more
doaj   +1 more source

Idiopathic pulmonary fibrosis in Sweden: report from the first year of activity of the Swedish IPF-Registry

European Clinical Respiratory Journal, 2016
Background Idiopathic pulmonary fibrosis (IPF) is an emerging problem in the western world, being related to increasing age and implying significant costs for the diagnosis and management of affected patients.
Giovanni Ferrara, Lisa Carlson, Andreas Palm, Jonas Einarsson, Cecilia Olivesten, Magnus Sköld, for the Swedish Idiopathic Pulmonary Fibrosis Registry Group   +6 more
doaj   +1 more source

Machine learning identified MDK score has prognostic value for idiopathic pulmonary fibrosis based on integrated bulk and single cell expression data

Frontiers in Genetics, 2023
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease that poses a significant challenge to medical professionals due to its increasing incidence and prevalence coupled with the limited understanding of its underlying molecular ...
Shichen Zhang, Lanlan Zhang, Lu Wang, Hongqiu Wang, Jiaxin Wu, Haoyang Cai, Chunheng Mo, Jian Yang   +7 more
doaj   +1 more source

Pirfenidone in idiopathic pulmonary fibrosis:expert panel discussion on the management of drug-related adverse events [PDF]

, 2014
Pirfenidone is currently the only approved therapy for idiopathic pulmonary fibrosis, following studies demonstrating that treatment reduces the decline in lung function and improves progression-free survival.
Per M. Hellström, Groves, Richard, Michael Kreuter, Toby M. Maher, Maher, Toby M, Dewint, P. (Pieter), Sarafidis, A. (Alexandre), Vancheri, C. (Carlo), Egan, Jim JJ, Bendstrup, Elisabeth, Maher, T.M. (Toby), Bendstrup, E. (Elisabeth), Sarafidis, Alexandre, Egan, Jim J J, Vancheri, Carlo, Jim J. J. Egan, Costabel, Ulrich, Ferguson, James, Vincent Cottin, Nordlind, K. (Klas), Cottin, V. (Vincent), Hellström, Per M, Maher, Toby M., Carlo Vancheri, Richard Groves, Groves, R. (Richard), Costabel, U., Klas Nordlind, Dewint, Pieter, Nordlind, Klas, Cottin, Vincent, Ulrich Costabel, Ferguson, J.J. (James), Hellström, A.-L., Alexandre Sarafidis, Pieter Dewint, Egan, Jim J. J., Elisabeth Bendstrup, Kreuter, M. (Michael), Maria Molina-Molina, Molina-Molina, M. (Maria), James Ferguson, Kreuter, Michael, Egan, J.J.J. (Jim J.), Molina-Molina, Maria, Hellström, Per M., Hellström, Per M.,   +46 more
core   +1 more source

Development and applicability of a dignity‐centred palliative care programme for people with idiopathic pulmonary fibrosis: A qualitative‐driven mixed methods study

Nursing Open, 2023
Aims This study evaluated the acceptability of a dignity‐centred palliative care programme for people with idiopathic pulmonary fibrosis by converging perceptions of living with idiopathic pulmonary fibrosis qualitative data and quantitative data. Design
Yasuko Igai, Sarah E. Porter
doaj   +1 more source

Magnetic resonance imaging as a non-invasive tool to investigate pulmonary and renal fibrosis in small rodents : method and readout validation, animal model optimization, and substance testing [PDF]

, 2015
Pulmonary fibrosis, an end result of various types of lung damage including interstitial pneumonia and respiratory bronchiolitis (Gross and Hunninghake, 2001; Katzenstein and Myers, 1998; Lazenby et al., 1990) is a lethal disease characterized by ...
Egger, Christine
core   +1 more source

Single-cell RNA-seq reveals ectopic and aberrant lung-resident cell populations in idiopathic pulmonary fibrosis

Science Advances, 2020
Human lung single-cell atlas reveals the complexity and diversity of aberrant cellular populations in pulmonary fibrosis. We provide a single-cell atlas of idiopathic pulmonary fibrosis (IPF), a fatal interstitial lung disease, by profiling 312,928 cells
T. Adams, J. Schupp, S. Poli, Ehab A. Ayaub, N. Neumark, F. Ahangari, S. Chu, Benjamin A. Raby, G. DeIuliis, Michael Januszyk, Qiaonan Duan, H. Arnett, Asim Siddiqui, G. Washko, R. Homer, Xiting Yan, I. Rosas, N. Kaminski   +17 more
semanticscholar   +1 more source

Precision medicine advances in idiopathic pulmonary fibrosis

EBioMedicine, 2023
Summary Idiopathic pulmonary fibrosis (IPF) is a highly heterogeneous, unpredictable and ultimately lethal chronic lung disease. Over the last decade, two anti-fibrotic agents have been shown to slow disease progression, however, both drugs are ...
T. Karampitsakos, B. Juan-Guardela, A. Tzouvelekis, J. Herazo-Maya   +3 more
semanticscholar   +1 more source